Page last updated: 2024-12-05

3,5-di-tert-butyl-4-hydroxybenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

3,5-di-tert-butyl-4-hydroxybenzoic acid, also known as butylated hydroxyanisole (BHA), is a synthetic antioxidant commonly used as a food additive to prevent rancidity. BHA is typically synthesized through the Friedel-Crafts alkylation of p-cresol with tert-butyl alcohol. BHA has been shown to exhibit anti-inflammatory and anti-cancer properties, although its potential health effects remain under investigation. BHA is widely studied for its antioxidant and anti-inflammatory properties, as well as its potential use in treating cancer and other diseases. BHA is an important compound due to its ability to inhibit oxidation and extend the shelf life of food products. '

Cross-References

ID SourceID
PubMed CID15007
CHEMBL ID119696
SCHEMBL ID227202
MeSH IDM0172550

Synonyms (60)

Synonym
unii-9f0i7yag34
9f0i7yag34 ,
4-10-00-00765 (beilstein handbook reference)
benzoic acid, 3,5-di-tert-butyl-4-hydroxy-
benzoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-
3,5-di-tert-butyl-4-hydroxybenzoic acid
einecs 215-823-2
3,5-bis-tert-butyl-4-hydroxybenzoic acid
3,5-di-t-butyl-4-hydroxybenzoic acid
brn 2216948
OPREA1_044717 ,
inchi=1/c15h22o3/c1-14(2,3)10-7-9(13(17)18)8-11(12(10)16)15(4,5)6/h7-8,16h,1-6h3,(h,17,18
3,5-di-tert-butyl-4-hydroxybenzoic acid, 98%
AC-11916
HMS1648L07
3,5-ditert-butyl-4-hydroxybenzoic acid
CHEMBL119696
AKOS001082280
1421-49-4
D2381
A807856
FT-0633532
AE-562/43460589
SCHEMBL227202
AB01334268-02
3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoic acid
f 2 (antioxidant)
2,6-di-tert-butyl-4-carboxyphenol
4-carboxy-2,6-di-tert-butylphenol
DTXSID3061683
TS-00782
3,5-bis-(1,1-dimetyletyl)-4-hydroxybenzenecarboxylic acid
4-hydroxy-3,5-di(tert.-butyl)benzoic acid
3,5-di-tert-butyl-4-hydroxy benzoic acid
3,5-di-tert-butyl4-hydroxybenzoic acid
3,5-di-tert-butyl4-hydroxy-benzoic acid
3,5-di-tert.-butyl-4-hydroxybenzoic acid
3,5-di-tert-butyl-4-hydroxy-benzoic acid
3,5-di-t-butyl-4-hydroxy-benzoic acid
4-hydroxy-3,5-di-tert-butyl benzoic acid
3,5-di-tert-butyl-4-hydroxybezoic acid
3,5-di-t-butyl4-hydroxybenzoic acid
3,5-bis(1,1-dimethylethyl)-4-hydroxy benzoic acid
3,5-di(t-butyl)-4-hydroxybenzoic acid
3,5-bis(1,1-dimethyethyl)-4-hydroxybenzoic acid
W-108178
3,5-di-tert-butyl-4-hydroxybenzoicacid
3,5-di(tert-butyl)-4-hydroxybenzoic acid
STR04340
3,5-di-t-butyl-4-hydroxy benzoic acid
mfcd00008827
sr-01000597216
SR-01000597216-1
SY048732
EN300-16635
D71197
Q27272465
NCGC00342102-01
CS-0154929
Z56347242

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The excretion rate of BHQ glucuronide for 24h after dosing with BHT-acid was about 9-fold higher than that after dosing with BHT."( Further metabolism of 3,5-di-tert-butyl-4-hydroxybenzoic acid, a major metabolite of butylated hydroxytoluene, in rats.
Mizutani, T; Tajima, K; Takemura, M; Yamamoto, K, 1991
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID736211Antidyslipidemic activity against triton WR1339-induced hyperlipidemia in rat assessed as reduction in plasma triglyceride level at 56 umol/kg, ip after 24 hrs (Rvb = 580%)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
AID438491Antioxidant activity in rat brain homogenate assessed as malondialdehyde release2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Novel compounds designed as antistress agents.
AID1365821Antioxidant activity in rat hepatic microsomes assessed as inhibition of FeSO4-induced lipid peroxidation measured after 45 mins by spectrophotometry2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Dual antioxidant structures with potent anti-inflammatory, hypolipidemic and cytoprotective properties.
AID736212Antidyslipidemic activity against triton WR1339-induced hyperlipidemia in rat assessed as reduction in plasma total cholesterol level at 56 umol/kg, ip after 24 hrs (Rvb = 260%)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
AID169468Comparative activity versus Dihydrodimethylbenzofurans in the CPE (Carrageenan paw edema) assay; (-) indicates the compound is inactive1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position.
AID647625Antioxidant activity assessed as trolox equivalent of ABTS radical scavenging activity relative to control2012European journal of medicinal chemistry, Apr, Volume: 50New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.67)18.7374
1990's4 (26.67)18.2507
2000's1 (6.67)29.6817
2010's6 (40.00)24.3611
2020's3 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.98 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]